2024 Advances in Lipid Management: A Year of Progress and Setbacks
2024: A Landmark Year in Lipid Management
Breakthroughs in Triglyceride and Lp(a) Management
In 2024, the field of lipidology witnessed significant advancements, particularly in the management of triglycerides and lipoprotein(a) (Lp(a)). Christie M. Ballantyne, MD, highlighted these developments at the Cardiometabolic Health Congress, emphasizing the progress made in clinical trials and regulatory approvals.
- Olezarsen for Familial Chylomicronemia Syndrome (FCS): The phase 3 BALANCE trial demonstrated that olezarsen, an antisense oligonucleotide, effectively reduced triglycerides in patients with FCS, leading to its FDA approval in December 2024. Ballantyne noted the therapy's impressive reduction in pancreatitis rates.
- Plozasiran's Breakthrough Therapy Designation: Another RNA interference agent, plozasiran, received FDA breakthrough therapy designation based on the phase 3 PALISADE trial results, showing significant triglyceride reduction and pancreatitis risk in FCS patients.
PCSK9 Inhibition and Novel Therapies
The year also saw progress in PCSK9 inhibition, with AstraZeneca's AZD0780 showing a 52% reduction in LDL in healthy adults. Additionally, the LIBerate studies highlighted the efficacy of lerodalcibep, an investigational biologic PCSK9 inhibitor, in maintaining LDL reductions over 72 weeks.
Challenges to the 'HDL Hypothesis'
The 'HDL hypothesis' faced another setback with the AEGIS II trial, which tested the investigational infusion CSL112 to boost HDL function. Despite not meeting its primary endpoint, a post hoc analysis suggested potential benefits in reducing CV death and MI, indicating the need for further research.
Looking Ahead
With ongoing trials and the development of novel therapies, the future of lipid management looks promising. However, the challenges faced by the 'HDL hypothesis' underscore the complexity of cardiovascular disease prevention and the need for continued innovation in lipidology.
References:
- AstraZeneca. A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD0780 in healthy subjects. Published June 2024.
- Björnson E, et al. J Am Coll Cardiol. 2024.
- Gibson CM, et al. Eur Heart J. 2024.